S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
Is This The End of Capitalism? (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
Is This The End of Capitalism? (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
Is This The End of Capitalism? (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:PCRX

Pacira BioSciences - PCRX Stock Forecast, Price & News

$39.40
+0.47 (+1.21%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$38.37
$39.54
50-Day Range
$35.53
$49.60
52-Week Range
$35.35
$82.16
Volume
331,676 shs
Average Volume
512,061 shs
Market Capitalization
$1.81 billion
P/E Ratio
96.10
Dividend Yield
N/A
Price Target
$65.50

Pacira BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
66.2% Upside
$65.50 Price Target
Short Interest
Bearish
11.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.91mentions of Pacira BioSciences in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$20,917 Sold Last Quarter
Proj. Earnings Growth
87.19%
From $2.03 to $3.80 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.48 out of 5 stars

Medical Sector

114th out of 1,054 stocks

Pharmaceutical Preparations Industry

42nd out of 517 stocks


PCRX stock logo

About Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Stock News Headlines

The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Wedbush Keeps Their Buy Rating on Pacira Pharmaceuticals (PCRX)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat
Pacira (PCRX) Lags Q3 Earnings Estimates
Pacira BioSciences: Q3 Earnings Insights
Assessing Pacira BioSciences' Growth Prospects
See More Headlines
Receive PCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pacira BioSciences and its competitors with MarketBeat's FREE daily newsletter.

PCRX Company Calendar

Last Earnings
11/03/2022
Today
1/29/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PCRX
CUSIP
69512710
Employees
697
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$65.50
High Stock Price Forecast
$88.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+66.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$41.98 million
Pretax Margin
3.85%

Debt

Sales & Book Value

Annual Sales
$541.53 million
Cash Flow
$3.54 per share
Book Value
$16.40 per share

Miscellaneous

Free Float
43,083,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
0.76

Key Executives

  • David M. StackDavid M. Stack
    Chairman & Chief Executive Officer
  • Daryl J. Gaugler
    Chief Operating Officer
  • Charles A. ReinhartCharles A. Reinhart
    Chief Financial Officer
  • Roy WinstonRoy Winston
    Chief Medical Officer
  • Charles Anthony Laranjeira
    Chief Technical Officer













PCRX Stock - Frequently Asked Questions

Should I buy or sell Pacira BioSciences stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pacira BioSciences in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCRX shares.
View PCRX analyst ratings
or view top-rated stocks.

What is Pacira BioSciences' stock price forecast for 2023?

6 Wall Street analysts have issued 1-year price targets for Pacira BioSciences' shares. Their PCRX share price forecasts range from $50.00 to $88.00. On average, they expect the company's share price to reach $65.50 in the next year. This suggests a possible upside of 66.2% from the stock's current price.
View analysts price targets for PCRX
or view top-rated stocks among Wall Street analysts.

How have PCRX shares performed in 2023?

Pacira BioSciences' stock was trading at $38.61 at the beginning of 2023. Since then, PCRX shares have increased by 2.0% and is now trading at $39.40.
View the best growth stocks for 2023 here
.

When is Pacira BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our PCRX earnings forecast
.

How were Pacira BioSciences' earnings last quarter?

Pacira BioSciences, Inc. (NASDAQ:PCRX) posted its quarterly earnings results on Thursday, November, 3rd. The company reported $0.42 EPS for the quarter, beating analysts' consensus estimates of $0.40 by $0.02. The business earned $167.47 million during the quarter, compared to the consensus estimate of $167.30 million. Pacira BioSciences had a net margin of 3.19% and a trailing twelve-month return on equity of 12.34%.

What guidance has Pacira BioSciences issued on next quarter's earnings?

Pacira BioSciences issued an update on its FY22 earnings guidance on Thursday, January, 5th. The company provided EPS guidance of at least $2.50 for the period, compared to the consensus earnings per share estimate of $2.64. The company issued revenue guidance of $666.8 million, compared to the consensus revenue estimate of $676.64 million.

What is Dave Stack's approval rating as Pacira BioSciences' CEO?

54 employees have rated Pacira BioSciences Chief Executive Officer Dave Stack on Glassdoor.com. Dave Stack has an approval rating of 45% among the company's employees. This puts Dave Stack in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pacira BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira BioSciences investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), ACADIA Pharmaceuticals (ACAD), Skyworks Solutions (SWKS), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Exelixis (EXEL) and Tesla (TSLA).

What is Pacira BioSciences' stock symbol?

Pacira BioSciences trades on the NASDAQ under the ticker symbol "PCRX."

Who are Pacira BioSciences' major shareholders?

Pacira BioSciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (4.07%), Stephens Investment Management Group LLC (2.55%), Rice Hall James & Associates LLC (0.95%), Peregrine Capital Management LLC (0.39%), Tributary Capital Management LLC (0.38%) and Scout Investments Inc. (0.32%). Insiders that own company stock include Andreas Wicki, Anthony Molloy, Charles A Reinhart III, Charles Anthony Laranjeira, Daryl Gaugler, David M Stack, David M Stack, Donald C Manning, Gary W Pace, John P Phd Longenecker, Jonathan Slonin, Kristen Marie Williams, Laura Brege, Lauren Bullaro Riker, Mark Froimson, Max Reinhardt, Paul J Hastings and Roy Winston.
View institutional ownership trends
.

How do I buy shares of Pacira BioSciences?

Shares of PCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pacira BioSciences' stock price today?

One share of PCRX stock can currently be purchased for approximately $39.40.

How much money does Pacira BioSciences make?

Pacira BioSciences (NASDAQ:PCRX) has a market capitalization of $1.81 billion and generates $541.53 million in revenue each year. The company earns $41.98 million in net income (profit) each year or $0.41 on an earnings per share basis.

How many employees does Pacira BioSciences have?

The company employs 697 workers across the globe.

How can I contact Pacira BioSciences?

Pacira BioSciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The official website for the company is www.pacira.com. The company can be reached via phone at (813) 553-6680, via email at susan.mesco@pacira.com, or via fax at 302-655-5049.

This page (NASDAQ:PCRX) was last updated on 1/29/2023 by MarketBeat.com Staff